Nick Olsen
Principal at Innovation Endeavors
San Francisco Bay Area
Overview
Work Experience
Principal
2023 - Current
investing at the intersection of technology, life sciences, and healthcare
Senior Associate
2022 - 2023
Associate
2021 - 2021
Innovation Endeavors invests in visionary founders, transformational technology, and emergent ecosystems for a new world.
Member Board of Directors
2024
Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.
Raised $82,000,000.00 from Arc Ventures, Innovation Endeavors, Deep Insight, Invus, Novartis Venture Fund, Insight Partners, Deep-Insight, JP Morgan, CRISPR Therapeutics and Delos Capital.
Member Board of Directors
2023 - 2024
Strategy and Operations
2018 - 2021
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions and deliver personalized patient care.
Senior Associate Consultant
2017 - 2018
Associate Consultant
2015 - 2017
Global Commercial
2017 - 2017
Spark Therapeutics is focused on the development of treatments for genetic diseases.
Raised $763,800,000.00 from Brookside Capital, Sofinnova Investments, Deerfield, Rock Springs Capital, T. Rowe Price and Wellington Management.